Clinical Trial Update: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tislelizumab with or without ociperlimab in recurrent or metastatic esophageal squamous cell carcinoma has completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Ociperlimab (ociperlimab)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2025-01-31